People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...